References
- 1. Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics, Accessed: May, 2018.
- 2. Ilic M, Ilic I. Cancer mortality in Serbia, 1991-2015: an age-period-cohort and joinpoint regression analysis. Cancer Commun (Lond). 2018 Apr 10;38(1):10.
- 3. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.
- 4. Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L’Allemain G, Bay JO. [Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer]. Bull Cancer. 2018;105(1):6-14.
- 5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302.
- 6. Albini A, Pannesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.
- 7. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21:173–179.
- 8. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–220.
- 9. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracicline therapy. JAMA. 1991;266:1672–1677.
- 10. Stevens PL, Lenihan DJ. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers. Curr Cardiol Rep. 2015 Jul;17(7):603.
- 11. ltena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–399.
- 12. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basicunder-lying mechanisms. Pharmacol Ther. 2018; S0163-7258(18)30072-X.
- 13. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Ver-rill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
- 14. SNPC. European Medicine Agency. Available in: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000682/human_med_001047.jsp&mid=WC0b01ac058001d124
- 15. Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemo-therapy. Drugs. 2005;68:1005–1024.
- 16. Csapo M, Lazar L. Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention. Clujul Medical. 2014;87(3):135-142.
- 17. SNPC. Food and Drug Agency. Available in: https://www.fda.gov/Drugs; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020212
- 18. Boucek RJ, Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3:319–29.
- 19. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469–73.
- 20. Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142:396–403.
- 21. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60:373–81.
- 22. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 2013; 61: 2355–2362.
- 23. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69: 695–699.
- 24. Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res 2001; 264: 244–249.
- 25. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011; 2: e190.
- 26. Ramanjaneyulu SV, Trivedi PP, Kushwaha S, Vikram A, Jena GB. Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem 2013; 69: 513–525.
- 27. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.
- 28. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.
- 29. Pimprapa V, Edward Y. Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. Journal of the American College of Cardiology. 2014; 64(9): 938-945.
- 30. Mônica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Vagner Oliveira Carvalho Rigaud, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity Journal of the American College of Cardiology. 2018; 71 (20) 2281-2290.
- 31. Purva Sharma, Stephanie Hakimian, Juan Camacho and Robert Chait. Prevention of chemo-induced cardiotoxicity with beta-blockers. Journal of the American College of Cardiology, 2018;71(11); DOI: 10.1016/S0735-1097(18)32344-1.
- 32. Escudier B, Alexandre JB, Leclercq B, Morin P, Guyot JM, Nitenberg G. Cardiotoxicitt du 5-fluorouracil. Caract Cristiques, mkanisme, conduite pratique. Presse Med 1986; 15:6-11.
- 33. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.
- 34. Puel C, Mathey J, Agalias A, Kati-Coulibaly S, Mardon J, et al. Dose–response study of effect of oleuropein, an olive oil polyphenol, in an ovariectomy/inflammation experimental model of bone loss in the rat. Clin. Nutr 2006; 25, 859–868.
- 35. Gülkaç MD, Akpinar G, Ustün H, Ozön Kanli A. Effects of vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats. Mutagenesis 2004; 19, 231–236.
- 36. Santos RV, Batista Jr, ML, Caperuto EC, Costa Rosa LF. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats. Clin. Exp. Pharmacol. Physiol. 2007; 34:1294–1299.
- 37. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther 2005; 4:110–130.
- 38. Huertas JR, Battino M, Lenaz G, Mataix FJ. Changes in mitochondrial and microsomal rat liver coenzyme Q9 and Q10 content induced by dietary fat and endogenous lipid peroxidation. FEBS Lett. 1991; 287:89–92.
- 39. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009;486:95–102.
- 40. Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP. Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol. Nutr. Food Res. 2009; 53, 600–608.
- 41. Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002; 180:79–95.
- 42. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. 2003; 3:16–24.
- 43. Lim HA, Kim JH, Kim JH, Sung MK, Kim MK, Park, JH, Kim JS. Genistein induces glucose-regulated protein 78 in mammary tumor cells. J. Med. Food 2006; 9:28–32.
- 44. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr. Rev. 2008; 66:445–454.
- 45. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A, et al. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol. Trace Elem. Res. 2009; 14:25-31.
- 46. Bulucu F, Oktenli C, Kenar L, Ocal R, Koc B, Inal V, Yamanel L, Yaman H, Sanisoglu YS, Aydin A. Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with adriamycin-induced nephrotic syndrome. J. Nephrol. 2008; 21: 576–583.
- 47. Jemai H, El Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. J. Agric. Food Chem. 2009; 57:8798–8804.
- 48. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008; 259:111–118.
- 49. Monstrey SJ, Mullick P, Narayanan K, et al. Hyperbaric oxygen therapy and free radical production: An experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:163-168.
- 50. Akta S, Toklu AS, Olgac V. Hyperbaric oxygen therapy in Adriamycin extravasation: An experimental animal study. Ann Plast Surg 2000; 45:167-171.
- 51. Karagoz B, Suleymanoglu S, Uzun G, Bilgi O, Aydinoz S, Haholu A, Turken O,Onem Y, Kandemir EG. Hyper-baric oxygen therapy does not potentiatedoxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol. 2008;102(3):287-92.
- 52. Goolsby, Tiffany V. et al. Extravasation of Chemotherapeutic Agents: Prevention and TreatmentSeminars in Oncology. 2006; 33(1); 139-143.
- 53. Newton RU, Galvão DA. Exercise in prevention and management of cancer. Curr Treat Options Oncol. 2008;9(2-3):135-46.
- 54. Rajarajeswaran P, Vishnupriya R. Exercise in cancer. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology. 2009;30(2):61-70.
- 55. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.
- 56. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. Jpn J Clin Oncol. 2016;34:2743–9.
- 57. Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009; 15:4963–7.
- 58. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology - Heart and Circula-tory Physiology. 2015; 309(9):H1453-H1467.
- 59. Fandeev OA, Vasechkin SS, Alekhin MN, Odintsov SV, Kallistov VE, Sidorenko BA. Clinical value of antracycline toxicity: modern approaches to diagnosis,prevention, and treatment. Kardiologiia. 2011; 51(7):40-6.